Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Baumer S.A. specializes in the development and manufacturing of precision medical instruments and supplies, primarily serving hospitals and healthcare facilities in Brazil and Latin America. The company differentiates itself through its high gross margins of 63.2% and a strong focus on innovation, particularly in minimally invasive surgical tools.
Baumer generates revenue through the sale of high-margin medical instruments and surgical supplies, leveraging its strong brand reputation and established relationships with healthcare providers. The company benefits from pricing power due to its focus on innovative products that enhance surgical outcomes.
Changes in healthcare regulations affecting medical device approvals
Demand for minimally invasive surgical instruments
Market expansion into other Latin American countries
Technological advancements in medical instrumentation
Regulatory changes in medical device approval processes
Technological disruption from new entrants in the medical device market
Increased competition from larger multinational medical device companies
Potential pricing pressures from generic medical supply manufacturers
Low liquidity risk due to a current ratio of 2.29
Potential risks associated with reliance on a limited number of key customers
moderate - as a healthcare supplier, Baumer's performance is somewhat insulated from economic downturns, but significant shifts in GDP can impact healthcare spending.
Low - the company has low debt levels (Debt/Equity of 0.14), minimizing the impact of rising interest rates on financing costs.
minimal - Baumer is not heavily reliant on credit for operations, given its strong cash flow and low debt levels.
growth - the company's focus on innovation and market expansion appeals to growth-oriented investors.
moderate - historical volatility is expected to be moderate due to the stability of the healthcare sector.